Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

446 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Absolute quantitative detection of ABL tyrosine kinase domain point mutations in chronic myeloid leukemia using a novel nanofluidic platform and mutation-specific PCR.
Oehler VG, Qin J, Ramakrishnan R, Facer G, Ananthnarayan S, Cummings C, Deininger M, Shah N, McCormick F, Willis S, Daridon A, Unger M, Radich JP. Oehler VG, et al. Among authors: deininger m. Leukemia. 2009 Feb;23(2):396-9. doi: 10.1038/leu.2008.183. Epub 2008 Jul 10. Leukemia. 2009. PMID: 18615105 Free PMC article. No abstract available.
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
Lange T, Deininger M, Brand R, Hegenbart U, Al-Ali H, Krahl R, Poenisch W, Uharek L, Leiblein S, Gentilini C, Petersdorf E, Storb RF, Niederwieser D. Lange T, et al. Among authors: deininger m. Leukemia. 2004 Sep;18(9):1468-75. doi: 10.1038/sj.leu.2403425. Leukemia. 2004. PMID: 15241437
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.
Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, Longtine J, Martinelli G, Saglio G, Soverini S, Stock W, Goldman JM. Hughes T, et al. Among authors: deininger m. Blood. 2006 Jul 1;108(1):28-37. doi: 10.1182/blood-2006-01-0092. Epub 2006 Mar 7. Blood. 2006. PMID: 16522812 Free PMC article. Review.
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Hochhaus A, et al. Among authors: deininger m. Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10. Leukemia. 2008. PMID: 18401416
Clonal chromosomal abnormalities in CD34+/CD38- hematopoietic cells from cytogenetically normal chronic myeloid leukemia patients with a complete cytogenetic response to tyrosine kinase inhibitors.
Bumm T, Deininger J, Newell AH, Lawce H, Olson S, Mauro M, Druker B, Deininger M. Bumm T, et al. Among authors: deininger j, deininger m. Leukemia. 2010 Aug;24(8):1525-1528. doi: 10.1038/leu.2010.123. Epub 2010 Jun 10. Leukemia. 2010. PMID: 20535153 Free PMC article. No abstract available.
446 results